DHR Earnings Prediction
The chart below shows how DHR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DHR sees a -0.93% change in stock price 10 days leading up to the earnings, and a -1.49% change 10 days following the report. On the earnings day itself, the stock moves by -0.78%. This data can give you a slight idea of what to expect for the next quarter's release.
DHR Key Earning Data
DHR Earnings Analysis
Positive
Earnings Per Share Beat: Danaher Corporation reported an EPS of $1.88, exceeding expectations of $1.63.
Stable Revenue Performance: First quarter revenue was $5.7 billion, with core revenue flat year-over-year, indicating stability in performance.
Gross Profit Margin Increase: Gross profit margin improved to 61.2%, up 100 basis points year-over-year, showcasing effective cost management.
Strong Cash Generation: Generated $1.1 billion in free cash flow, resulting in a conversion ratio of over 110%, reflecting strong cash generation capabilities.
Long-Term Growth Investments: Significant investments in long-term growth initiatives led to impactful new product launches, reinforcing competitive advantages.
Biotechnology Revenue Increase: Biotechnology segment core revenue increased by 7%, driven by strong demand in bioprocessing and consumables.
Bioreactor Format Launch: Cytiva launched new bioreactor formats aimed at increasing productivity in biologic drug manufacturing.
FDA Clearance for DxC 500i: Beckman Coulter Diagnostics received FDA clearance for the DxC 500i analyzer, enhancing its product portfolio for low-volume labs.
Respiratory Revenue Surge: Cepheid's respiratory revenue exceeded expectations, driven by elevated demand and share gains, indicating strong market position.
Core Revenue Growth Outlook: The company expects core revenue growth of approximately 3% for the full year 2025, maintaining a positive outlook despite market challenges.
Negative
Flat Core Revenue: Core revenue was flat year-over-year, indicating a lack of growth in sales performance.
Developed Markets Revenue Decline: Core revenues in developed markets were down slightly, with a low-single digit decline in North America.
China Market Decline: High growth markets saw a high-single digit decline within China, primarily due to volume-based procurement and reimbursement changes.
Operating Profit Margin Decline: Adjusted operating profit margin decreased by 50 basis points, suggesting increased costs that were not fully offset by revenue growth.
Life Sciences Revenue Decline: Core revenue in the Life Sciences segment decreased by 4%, indicating challenges in that area.
Sector Demand Softening: Demand in academic and government sectors softened, particularly in the United States, which could impact future growth.
Genomics Consumables Revenue Decline: Core revenue in genomics consumables declined, with weaker demand for plasmids and mRNA at two larger customers.
Modest Core Revenue Growth: The company expects core revenue growth of only approximately 3% for the full year 2025, reflecting modest expectations for life sciences.
DHR FAQs
How does DHR typically perform around its earnings report dates?
DHR's stock performance around earnings reports can vary, but historical data shows specific patterns, such as a -0.93% change leading up to the report and a -1.49% change in the 10 days following the release.
Is Danaher Corp (DHR) Q1 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
DHR Earning Call Sentiment
Danaher Corporation (NYSE:DHR) Q1 2025 Earnings Call Transcript
DHR.N
-4.47%
